<DOC>
	<DOCNO>NCT02058277</DOCNO>
	<brief_summary>This open label , randomize , single dose , one cohort , two sequence , two period crossover study healthy subject . The primary objective study evaluate effect single oral dose aprepitant pharmacokinetic ( PK ) profile single oral dose bosutinib healthy subject .</brief_summary>
	<brief_title>A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Healthy male and/or female subject inform consent document sign date subject . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method non hormonal contraception outline protocol . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>bosutinib</keyword>
	<keyword>aprepitant</keyword>
	<keyword>drug interaction</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
</DOC>